volume 26, issue 4, P931-948 2012
DOI: 10.1016/j.idc.2012.08.004
View full text
|
|
Share
Vincent Soriano, Pablo Labarga, Eugenia Vispo, José Vicente Fernández-Montero, Pablo Barreiro

Abstract: Chronic hepatitis C is a leading cause of clinical complications and mortality in individuals infected with human immunodeficiency virus (HIV). Approval for the first direct-acting antiviral (DAA) against the hepatitis C virus (HCV) has been eagerly awaited for treating patients coinfected with HIV/HCV. The use of first-generation HCV protease inhibitors is challenged by complicated dosing schedules, frequent serious toxicities, unwanted drug interactions, drug resistance, and high cost. First-generation DAAs …

expand abstract